70-80% Decline In Participants For Phase3 Trial Of Bharat Biotech's Covaxin | Read

While the ICMR (Indian Council of Medical Research) has announced that results of Phase 1 trial of Covid vaccine candidate Covaxin, developed by Bharat Biotech, are "encouraging", the third phase of trials, which are currently going on in India, are facing challenges. According Dr Sanjay Rai, Principal Investigator of Phase 3 Covaxin trial at All India Institute of Medical Sciences (AIIMS), there is a 70% to 80% reduction in participation for the Covaxin trial. People are unwilling to participate in the trial because they think that a vaccine is coming for everyone soon. The AIIMS in Delhi needs 1,500 to 2,000 participants for Phase 3 trial of Covaxin, but only 200 have enrolled so far.